Patents by Inventor Marcus Koppitz
Marcus Koppitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11529356Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 21, 2020Date of Patent: December 20, 2022Assignee: Bayer Pharma AktiengesellschaftInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Patent number: 11319324Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 18, 2018Date of Patent: May 3, 2022Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Marcus Koppitz, Holger Siebeneicher, Nico Bräuer, Elisabeth Pook, Andrea Rotgeri, Roland Neuhaus, Oliver Martin Fischer, Jens Nagel, Adam James Davenport, James Lindsay Carr, Robert James Townsend, Nina Connelly Ursinyova, Shelley Anne Parrott
-
Publication number: 20210317128Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 18, 2018Publication date: October 14, 2021Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Nico BRÄUER, Elisabeth POOK, Andrea ROTGERI, Roland NEUHAUS, Oliver Martin FISCHER, Jens NAGEL, Adam James DAVENPORT, James Lindsay CARR, Robert James TOWNSEND, Nina CONNELLY URSINYOVA, Shelley Anne PARROTT
-
Patent number: 10894784Abstract: The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: December 15, 2016Date of Patent: January 19, 2021Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Volker Schulze, Tobias Heinrich, Florian Prinz, Julien Lefranc, Jens Schröder, Anne Mengel, Wilhelm Bone, Joszef Bálint, Antje Margret Wengner, Knut Eis, Horst Irlbacher, Marcus Koppitz, Ulf Bömer, Benjamin Bader, Hans Briem, Philip Lienau, Clara Christ, Detlef Stöckigt, Roman Hillig
-
Publication number: 20200383991Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 21, 2020Publication date: December 10, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Patent number: 10772893Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 8, 2018Date of Patent: September 15, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Patent number: 10730856Abstract: The present invention relates to novel benzimidazole derivatives of the general formula (I), to processes for their preparation and to their use for preparing pharmaceutical compositions for the treatment of disorders and indications associated with the EP4 receptor.Type: GrantFiled: December 16, 2014Date of Patent: August 4, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Olaf Peters, Nico Bräuer, Ulrich Bothe, Marcus Koppitz, Jens Nagel, Gernot Langer
-
Patent number: 10729680Abstract: The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: January 6, 2017Date of Patent: August 4, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Lücking, Marcus Koppitz, Julien Lefranc, Lars Wortmann, Antje Margret Wengner, Gerhard Siemeister, Ulf Bömer, Benjamin Bader, Philip Lienau, Hans Schick
-
Publication number: 20200123147Abstract: The present invention provides PRMT5 inhibiting compounds of general formula (I): A compound of general formula (I), in which R1, R2, R3 R4, R5, R6, R7 L1 and L2 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: June 21, 2018Publication date: April 23, 2020Inventors: Lea Aurelie BOUCHE, Duy NGUYEN, Daniel KORR, Marcus KOPPITZ, Antonius TER LAAK, Amaury Ernesto FERNANDEZ-MONTALVAN, Thi Thanh Uyen NGUYEN, Stefan PRECHTL, Andreas JANZER
-
Publication number: 20200087284Abstract: The present invention covers [4-(phenylsulfonyl)piperazin-1-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 15, 2017Publication date: March 19, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Holger STEUBER, Antonius TER LAAK, Reinhard NUBBEMEYER, Antje ROTTMANN, Horst IRLBACHER, Benjamin BADER, Michaele PETERS, Andrea WAGENFELD
-
Publication number: 20200085791Abstract: The present invention covers [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1H-1,2,3-triazol-5-yl)methanone compounds of general formula (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 15, 2017Publication date: March 19, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Holger STEUBER, Antonius TER LAAK, Reinhard NUBBEMEYER, Antje ROTTMANN, Horst IRLBACHER, Benjamin BADER, Michaele PETERS, Andrea WAGENFELD
-
Publication number: 20200079758Abstract: The present invention covers [4-(phenylsulfonyl)piperazin-1-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 15, 2017Publication date: March 12, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Holger STEUBER, Antonius TER LAAK, Reinhard NUBBEMEYER, Antje ROTTMANN, Horst IRLBACHER, Benjamin BADER, Michaele PETERS, Andrea WAGENFELD
-
Publication number: 20190142812Abstract: The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: January 6, 2017Publication date: May 16, 2019Inventors: Ulrich LÜCKING, Marcus KOPPITZ, Julien LEFRANC, Lars WORTMANN, Antje Margret WENGNER, Gerhard SIEMEISTER, Ulf BÖMER, Benjamin BADER, Philip LIENAU, Hans SCHICK
-
Publication number: 20190047980Abstract: The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 15, 2016Publication date: February 14, 2019Inventors: Volker SCHULZE, Tobias HEINRICH, Florian PRINZ, Julien LEFRANC, Jens SCHRÖDER, Anne MENGEL, Wilhelm BONE, Joszef BÁLINT, Antje Margret WENGNER, Knut EIS, Horst IRLBACHER, Marcus KOPPITZ, Ulf BÖMER, Benjamin BADER, Hans BRIEM, Philip LIENAU, Clara CHRIST, Detlef STÖCKIGT, Roman HILLIG
-
Patent number: 10172814Abstract: The present invention relates to substituted Pyridyl-cycloalkyl-carboxylic acids of general formula (I), to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular in mammals, such as diseases associated with pains, or for the treatment or prophylaxis of pain syndromes (acute and chronic), inflammatory-induced pain, pelvic pain, cancer-associated pain, endometriosis-associated pain as well as endometriosis and adenomyosis as such, cancer as such, and proliferative diseases as such like endometriosis.Type: GrantFiled: December 16, 2015Date of Patent: January 8, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Nico Bräuer, Jens Nagel, Horst Irlbacher, Andrea Rotgeri, Wolfgang Schwede, Henrik Dahllöf, Marcus Koppitz, Michaele Peters, Anne-Marie Godinho-Coelho
-
Patent number: 10167293Abstract: The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 16, 2017Date of Patent: January 1, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Marcus Koppitz, Holger Siebeneicher, Holger Steuber, Antonius Ter Laak, Reinhard Nubbemeyer, Antje Rottmann, Horst Irlbacher, Benjamin Bader, Michaele Peters, Andrea Wagenfeld, Ildiko Terebesi
-
Publication number: 20180319807Abstract: The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 16, 2017Publication date: November 8, 2018Inventors: Marcus KOPPITZ, Holger SIEBENEICHER, Holger STEUBER, Antonius TER LAAK, Reinhard NUBBEMEYER, Antje ROTTMANN, Horst IRLBACHER, Benjamin BADER, Michaele PETERS, Andrea WAGENFELD, Ildiko TEREBESI
-
Publication number: 20180256591Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 8, 2018Publication date: September 13, 2018Inventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Patent number: 9993484Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 3, 2015Date of Patent: June 12, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Wortmann, Ulrich Lücking, Julien LeFranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Publication number: 20180148418Abstract: The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredient.Type: ApplicationFiled: May 2, 2016Publication date: May 31, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Knut EIS, Jens ACKERSTAFF, Sarah WAGNER, Philipp BUCHGRABER, Detlev SÜLZLE, Simon HOLTON, Eckhard BENDER, Volkhart LI, Ningshu LIU, Franziska SIEGEL, Philip LIENAU, Michaela BAIRLEIN, Franz VON NUSSBAUM, Simon Anthony HERBERT, Marcus KOPPITZ